Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

@inproceedings{Ke2016TowardsAB,
  title={Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6},
  author={Alice Ke and Zoe E Barter and K Rowland‐Yeo and Lisa Almond},
  booktitle={CPT: pharmacometrics & systems pharmacology},
  year={2016}
}
In this study, we present efavirenz physiologically based pharmacokinetic (PBPK) model development as an example of our best practice approach that uses a stepwise approach to verify the different components of the model. First, a PBPK model for efavirenz incorporating in vitro and clinical pharmacokinetic (PK) data was developed to predict exposure following multiple dosing (600 mg q.d.). Alfentanil i.v. and p.o. drug-drug interaction (DDI) studies were utilized to evaluate and refine the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.

Clinical pharmacology and therapeutics • 2012
View 5 Excerpts
Highly Influenced

Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.

Xenobiotica; the fate of foreign compounds in biological systems • 2009
View 2 Excerpts
Highly Influenced

Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.

Journal of acquired immune deficiency syndromes • 2008
View 3 Excerpts
Highly Influenced

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model

Drug metabolism and disposition: the biological fate of chemicals • 2016
View 1 Excerpt

Pharmacokinetic and pharmacodynamic comparison of once - daily efavirenz ( 400 mg vs . 600 mg ) in treatment - na € ı ve HIV - infected patients : results of the ENCORE 1 study

L. Dickinson
Clin . Pharmacol . Ther . • 2015